Study for Adults with Newly Diagnosed or Recurrent Glioblastoma (GBM)

IRB/UVA Tracking #
Principal Investigator
David Schiff
Carol Woodburn
Contact Email
Contact Phone
Official Trial Title
A Phase 1b/2 study to assess the safety, tolerability
and efficacy of BGB-290 in combination with radiation
therapy and/or temozolomide in subjects with first-line
or recurrent/refractory glioblastoma
Study Description

The Division of Neuro-Oncology seeks adult men and women ages 18 and older with newly diagnosed or recurrent glioblastoma (GBM) for a research study. The purpose of this study is to look at the safety, tolerability, and efficacy of an investigational anti-cancer drug called BGB-290 (a PARP inhibitor) when it is given alone or with another anti-cancer treatment, temozolomide (TMZ), with or without treatment with radiation.

You may be eligible for this study if:
You have been newly diagnosed with glioblastoma with an unmethylated MGMT promoter status OR You have been diagnosed with recurrent glioblastoma.

Study involves taking an experimental medicine by mouth, blood draws, physical exams, ECGs, and possibly treatment with radiation and TMZ, depending on the study arm (A, B, or C) to which you are assigned. Visits will vary based upon study arm assignment, but could be as often as weekly for the first 6 weeks.

Study-related exams, blood draws, and study medication will be provided free of charge.